Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VAFSEO vs RETACRIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
VAFSEO (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-α, leading to increased transcription of genes involved in erythropoiesis, including erythropoietin, enhancing red blood cell production.
RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
Treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis
Treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis,Treatment of anemia in HIV-infected patients treated with zidovudine,Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy,Reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery
Oral: 20 mg three times weekly for 24 weeks.
50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/d L.
Terminal half-life is approximately 20-30 hours, supporting once-daily dosing.
Terminal elimination half-life is ~2.5-4.5 hours following intravenous administration; shorter in children; prolonged in hepatic impairment.
Primarily metabolized by CYP2C8 and UGT1A9; minor pathways include CYP3A4 and CYP2C9.
Epoetin alfa-epbx is a protein; metabolism is expected to involve proteolytic degradation via catabolic pathways, similar to endogenous erythropoietin. No specific metabolic enzymes have been identified; clearance is primarily through receptor-mediated uptake and proteolysis.
Primarily fecal (approximately 81%) and renal (~17%) as unchanged drug and metabolites.
Primarily hepatic metabolism; ~10% excreted unchanged in urine, remainder via feces as metabolites.
~50% bound to plasma proteins, primarily albumin.
Primarily binds to transferrin; iron is 100% bound to transferrin after dissociation from complex.
Apparent volume of distribution is approximately 1.5 L/kg, indicating extensive extravascular distribution.
Vd is approximately 0.067-0.22 L/kg; reflects distribution into plasma and extracellular fluid; limited tissue penetration initially.
Oral bioavailability is approximately 60-70% (not affected by food).
Not orally bioavailable; administered intravenously (100% bioavailability for IV route).
No dosage adjustment required for any degree of renal impairment.
For CKD patients, epoetin alfa dosing is independent of GFR; adjust based on hemoglobin response. No specific GFR-based dose adjustments, but start at 50-100 IU/kg three times weekly for dialysis patients.
No dosage adjustment required for mild to severe hepatic impairment (Child-Pugh A, B, or C).
No specific Child-Pugh based adjustments. Use with caution in severe hepatic impairment; monitor for adverse effects.
Safety and efficacy not established in pediatric patients.
0.5-50 IU/kg subcutaneously or intravenously three times weekly, titrated to target hemoglobin. For pediatric CKD, initial dose 50 IU/kg three times weekly.
No specific dose adjustment recommended; use with caution due to limited data.
No specific dose adjustment; initiate at lower end of dosing range (50 IU/kg three times weekly) and titrate slowly, monitoring for hypertension and thrombotic events.
Increased risk of thrombosis, including vascular access thrombosis, deep vein thrombosis, pulmonary embolism, and myocardial infarction. Not approved for use in patients with active malignancy due to potential for tumor progression.
WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE. Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of 13 g/d L or greater. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest dose sufficient to reduce the need for red blood cell transfusions. Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs only for anemia from myelosuppressive chemotherapy. ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure. Discontinue following the completion of a chemotherapy course. Perisurgery: Due to increased risk of deep venous thrombosis (DVT), use prophylactic anticoagulation and consider whether benefit of transfusion reduction outweighs increased risk of post-operative thrombotic/vascular events.
Thrombotic events,Increased mortality in patients with cancer,Hypertension,Seizures,Gastric erosion and bleeding,Serious hepatotoxicity,Potential for tumor growth,Not for treatment of anemia due to other causes,Monitor hemoglobin levels
Increased mortality, myocardial infarction, stroke, and thromboembolism,Increased risk of thrombosis of vascular access,Increased mortality and/or tumor progression in cancer patients,Hypertension,Seizures,Pure red cell aplasia (PRCA) due to anti-erythropoietin antibodies,Serious allergic reactions,Possible worsening of anemia due to antibody-mediated PRCA,Risk of cardiovascular events when hemoglobin exceeds 11 g/d L,Need for iron supplementation,Monitoring of hemoglobin and blood pressure
Uncontrolled hypertension,Active malignancy,History of thrombotic events (relative),Hypersensitivity to vadadustat or any component
Uncontrolled hypertension,Pure red cell aplasia (PRCA) that begins after treatment with epoetin alfa or other ESAs,Known hypersensitivity to epoetin alfa-epbx or any component of the product
No significant food interactions. May be taken with or without food. Avoid grapefruit products as they may increase drug levels (moderate CYP3A4 interaction).
No specific food interactions. Maintain adequate iron intake; consider dietary sources of iron (e.g., red meat, leafy greens) if not on supplements. No restrictions with alcohol or other foods.
Vafseo (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor. There are no adequate human data on teratogenic risk. In animal studies, vadadustat caused embryofetal toxicity (reduced fetal weight, skeletal variations) at exposures similar to human exposure at the maximum recommended human dose. Based on mechanism of action, potential risks include impaired implantation and fetal development. First trimester: unknown risk; second and third trimesters: potential fetal hypoxia from altered erythropoiesis. Vafseo should be avoided during pregnancy unless clearly needed.
Retacrit (epoetin alfa-epbx) is a recombinant human erythropoietin. In animal studies, epoetin alfa did not demonstrate teratogenicity at clinically relevant doses. However, there are no adequate and well-controlled studies in pregnant women. Potential fetal risks include hypertension and thromboembolic events secondary to maternal polycythemia. Use during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. The molecular weight (~340 Da) suggests potential excretion. Due to potential for serious adverse reactions (e.g., effects on erythropoiesis), breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose. M/P ratio: unknown.
It is not known whether epoetin alfa is excreted in human milk. Endogenous erythropoietin is present in breast milk. M/P ratio not available. Caution should be exercised when Retacrit is administered to a nursing woman. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed child from the drug or underlying maternal condition.
No specific dose adjustments established for pregnancy. Pharmacokinetics may be altered due to increased plasma volume and renal clearance, potentially requiring higher doses. However, lack of safety data precludes routine use; if necessary, use lowest effective dose and monitor hemoglobin closely to avoid excessive erythropoiesis. Consider avoiding use altogether.
No specific dose adjustments for Retacrit are recommended during pregnancy based on pharmacokinetic changes. However, pregnant women may have increased plasma volume and altered erythropoietin kinetics. The lowest effective dose to gradually increase hemoglobin to the target level (not to exceed 12 g/d L in chronic kidney disease) should be used. Close monitoring of hemoglobin and blood pressure is essential to avoid excessive erythrocytosis and associated risks.
VAFSEO (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for anemia due to chronic kidney disease (CKD). Monitor hemoglobin every 2 weeks during dose titration; target Hb ≤11 g/d L to reduce thrombotic risk. Avoid in patients with active malignancy due to potential tumor growth promotion. Drug interactions: reduce dose of VAFSEO when co-administered with strong CYP2C8 inhibitors (e.g., gemfibrozil); avoid with rifampin. Do not use erythropoiesis-stimulating agents concurrently. Assess iron stores and replete iron as needed.
Retacrit (epoetin alfa-epbx) is a biosimilar to Epogen/Procrit. Monitor hemoglobin weekly until stable, then monthly; target Hb 10-12 g/d L. Do not use to replace urgent transfusions. Iron stores must be adequate; check ferritin and transferrin saturation. Increased risk of thrombotic events, especially in patients with cardiovascular disease. Do not shake vial; use one vial per dose; discard unused portion. Administer subcutaneously or intravenously; rotate injection sites.
Take VAFSEO exactly as prescribed, usually once daily with or without food.,Do not take VAFSEO if you have active cancer or are being treated for cancer.,Report signs of blood clots (e.g., leg swelling, chest pain, sudden shortness of breath) immediately.,Do not use other anemia medications (e.g., epoetin alfa) while on VAFSEO unless told by your doctor.,You will need regular blood tests to monitor hemoglobin and iron levels.,Take iron supplements if prescribed by your doctor; do not take additional iron without consulting your healthcare provider.,Inform all healthcare providers that you are taking VAFSEO.
This medication helps your body make more red blood cells to treat anemia.,You will have regular blood tests to check your hemoglobin levels and iron stores.,Do not miss scheduled appointments for monitoring; call your doctor if you have symptoms of a blood clot (chest pain, sudden shortness of breath, leg swelling).,It is important to take iron supplements as prescribed while on this medication.,Store Retacrit in the refrigerator; do not freeze or shake the vial.,Report any signs of allergic reaction (rash, itching, swelling).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VAFSEO vs RETACRIT, answered by our medical review team.
VAFSEO is a Erythropoiesis-Stimulating Agent that works by VAFSEO (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-α, leading to increased transcription of genes involved in erythropoiesis, including erythropoietin, enhancing red blood cell production.. RETACRIT is a Erythropoiesis-Stimulating Agent that works by RETACRIT (epoetin alfa-epbx) is a recombinant human erythropoietin that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VAFSEO and RETACRIT depend on the specific clinical indication. These are both Erythropoiesis-Stimulating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VAFSEO is: Oral: 20 mg three times weekly for 24 weeks.. The standard adult dose of RETACRIT is: 50-100 IU/kg intravenously or subcutaneously three times weekly; initial dose 50 IU/kg three times weekly, titrated to target hemoglobin 10-12 g/d L.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VAFSEO and RETACRIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VAFSEO is classified as Category C. Vafseo (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor. There are no adequate human data on teratogenic risk. In animal studies, vadadustat caused embryofet. RETACRIT is classified as Category C. Retacrit (epoetin alfa-epbx) is a recombinant human erythropoietin. In animal studies, epoetin alfa did not demonstrate teratogenicity at clinically relevant doses. However, there . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.